Table 1 Characteristics of the patients at baseline
Characteristic | Value (N = 25) |
|---|---|
Age, years, median (range) | 44 (24–60) |
Gender, no. (%) | |
Female | 4 (16) |
Male | 21 (84) |
ECOGa performance-status score, no. (%) | |
0 | 19 (76) |
1 | 6 (24) |
Initial stageb, no. (%) | |
II–III | 9 (36) |
IVa | 10 (40) |
IVb | 6 (24) |
Location of recurrences/metastases, no. (%) | |
Local recurrence | 2 (8) |
Regional lymph nodes | 3 (12) |
Liver | 12 (48) |
Lung | 10 (40) |
Distant lymph nodes | 13 (52) |
Bone and soft tissue | 15 (60) |
EBV DNA copy number, no. (%) | |
≤ 3000 copies/mL | 13 (52) |
> 3000 copies/mL | 12 (48) |
Time from initial cancer diagnosis to study enrollment, months, median (range) | 25.43 (6.2–105.43) |
Prior radiotherapy, no. (%) | |
Yes | 22 (88) |
None | 3 (12) |
Prior therapy lines for advanced disease, no. (%) | |
1 | 16 (64) |
2 | 3 (12) |
≥ 3 | 6 (24) |
ICI-free interval, months, median (range) | 2.03 (0.7–16.03) |
No. of types of prior ICI, no. (%) | |
1 | 20 (80) |
2 | 4 (16) |
3 | 1 (4) |
Previous treatment for advanced disease | |
PD-1 inhibitor, no. (%) | 25 (100) |
Toripalimab | 13 (52) |
Camrelizumab | 8 (32) |
Sintilimab | 5 (20) |
Palivizumab | 2 (8) |
Tislelizumab | 1 (4) |
Other therapy, no. (%) | 25 (100) |
Cisplatin | 24 (96) |
Gemcitabine | 22 (88) |
Paclitaxel | 10 (40) |
Capecitabine | 5 (20) |
Nimotuzumab | 4 (16) |
Carboplatin | 2 (8) |
Tegafur | 2 (8) |
Apatinib | 1 (4) |
Cetuximab | 1 (4) |
Anlotinib | 1 (4) |
Bevacizumab | 1 (4) |